BLFS BioLife Solutions, Inc.
USHealthcareAs of 2026-07-09 16:00
Why BLFS matters now
BioLife Solutions, Inc. (BLFS) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.23 with +3.82% on the session and $1.38B in market capitalization; recent performance reads 1-month +12.97% and YTD +7.69%.
The latest financial table shown here is Q1 2026, with revenue of $27.5M, net income of $1.2M, and EPS of $0.02. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.1%.
The latest indexable market news headline is "BioLife Solutions Inc (BLFS) Stock Up 3.1% and Still Undervalued -- GF Score: 73/100" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $34.00; recent insider activity includes Mathew Aby J. filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.39
P/S
12.75
EV/EBITDA
-169.47
DCF Value
$-4.19
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.9%
Operating Margin
-10.9%
Net Margin
-10.5%
ROE
-2.9%
ROA
-2.6%
ROIC
-2.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $27.5M | $1.2M | $0.02 |
| Q4 2025 | $18.8M | $3.5M | $0.08 |
| FY 2025 | $96.2M | $-12.1M | $-0.25 |
| Q3 2025 | $28.1M | $621.0K | $0.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$34.00
Target (Median)
$34.00
Target Range
$34.00 - $34.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.97
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.